Kindred Biosciences Inc

Kindred Biosciences — Investor Presentation (January 2016)

40 slides from Kindred Biosciences's investor presentation, Jan 11, 2016

  1. Slide 1: KindredBio: Best Medicines for Our Best Friends

    1 KindredBio Best Medicines for Our Best Friends

  2. Slide 2: Forward Looking Statements

    2 Forward Looking Statements This presentation contains forward-looking statements, including but not limited to statements regarding the timing of development for our product candidates, expected commencement and completion of pivotal trials, prospective product candidates, anticipated regulatory a

  3. Slide 3: We Love Our Pet Family Members

    3 We Love Our Pet Family Members $15.25 billion on veterinary care $1.5 billion on dog knee surgeries $370 million on pet Halloween costumes $700 million on Valentine’s Day gifts Annually, U.S. pet parents estimated to spend:

  4. Slide 4: Bring the very best science and medicine to our animal family members

    4 Bring the very best science and medicine to our animal family members. KindredBio

  5. Slide 5: KindredBio's Strategy: Repurpose Human Drugs for Pets

    5 KindredBio’s Strategy: Repurpose Human Drugs for Pets Pursue molecules already known to work Reduce technical risk Reduce timelines $3M-$5M to develop each pet drug Reduce financing risk Portfolio approach

  6. Slide 6: KindredBio Highlights

    6 KindredBio Highlights Less than 2 Years to Launch KIND-012 for fever in horses KIND-010 for weight loss in cats 2+ launches per year thereafter Attractive Markets Rapidly growing Few current competitors World Class Team Extensive drug development experience Human and veterinary experience Deep Pip

  7. Slide 7: World Class Leadership Team

    7 Richard Chin, M.D. Founder and Chief Executive Officer Former Head of Clinical Research, BioTherapeutics, Genentech Rhodes Scholar World Class Leadership Team 7 Denise Bevers​ Founder and Chief Operating Officer Founder, SD Scientific; 25 years in biotech/pharma Stephen Sundlof, D.V.M, Ph.D. Chief

  8. Slide 8: Deep Product Pipeline

    8 Molecule Indication Discovery/Process Development Pilot Studies Pivotal Clinical Studies NADA & Launch Preparation Biologic Product Candidates Feline Epo Anemia in cats Anti-Interleukin Antibodies Atopic dermatitis in dogs Checkpoint Inhibitors Cancer in dogs Anti-CD20 antibody Cancer and autoimmu

  9. Slide 9: Key Strengths

    9 Key Strengths Validated, repurposed molecules Avoid risks associated with new chemical entities Reduced costs and timelines, including for API No royalties/milestones Expertise in biologics In-house clinical development capabilities Reduced costs and timelines by not having to rely on CROs Focus o

  10. Slide 10: Market Opportunity

    10 Market Opportunity

  11. Slide 11: Veterinary Market is Growing Rapidly

    11 $9.3 $15.3 $0 $2 $4 $6 $8 $10 $12 $14 $16 $18 2006 2014 Sp e n d in g in B ill ion s Veterinary Market is Growing Rapidly The veterinary care market grew 65% from 2006 to 2014 Source: APPA Pet Industry Market Size & Ownership Statistics 2014 & TriMark Vet Health Market, June 2013 Estimated

  12. Slide 12: There is a High Willingness to Pay

    12 There is a High Willingness to Pay… $500 $1,000 $2,000 $5,000 Extremely/Very likely 62% 42% 35% 22% Somewhat likely 18% 20% 28% 20% Not too likely/Not at all likely 18% 36% 36% 55% Don’t know 1% 2% 1% 3% Pet owners are willing to spend on their seriously ill pets if they require medical treatment

  13. Slide 13: But Treatment Options are Limited

    13 …But Treatment Options are Limited Underserved market with attractive growth opportunities Few competing biotechs Large pharma focused on blockbusters On average, less than a dozen pet drugs are approved annually by the FDA In 2014 the FDA approved: 6 pet drugs 41 humans drugs

  14. Slide 14: Veterinary Pharmaceuticals Field

    14 Veterinary Pharmaceuticals Field We believe there are similarities between veterinary pharmaceutical field now and the human pharmaceutical field in its early stages: Similar regulatory standards Similar commercial and reimbursement landscape Similar development costs Numerous untapped opportunit

  15. Slide 15: Veterinary vs. Human Markets

    15 Veterinary vs. Human Markets Can reach market in 3-5 years Faster Development Lower Development Cost Almost no biotechs, almost no generics Lower Competition Self-Pay Very few reimbursement hurdles Can develop for $3M-$5M per product

  16. Slide 16: Programs

    16 Programs

  17. Slide 17: KindredBio Strategy

    17 KindredBio Strategy Already validated in humans & established manufacturing Customize species- specific dosage and formulate flavored/convenient delivery Targets based on approved human drugs (e.g., Enbrel and Orencia) Create canine/ feline/equine versions of biologics with the same or similar ta

  18. Slide 18: KindredBio's Priority Areas

    18 Equine Products • High willingness to pay • Similar to human orphan drug market • Efficient commercial structure Biologics • Atopic dermatitis • Cancer KindredBio’s Priority Areas

  19. Slide 19: Equine Market

    19 Equine Market Fewer horses than cats or dogs, but higher willingness to pay – similar to human orphan drug markets Only 10-12 sales representatives required for full national coverage Underappreciated opportunity KindredBio’s goal is to become dominant company in the equine sector

  20. Slide 20: KIND-012: Treating Fever in Horses

    20 KIND-012 IV and oral drug for treating fever in horses High unmet medical need Over 50% of equine veterinarians treat 1-3 fevers per month (~35% treat 6-10 fevers per month) IV: Positive pilot study completed Positive pivotal field study completed Target Animal Safety Study (TASS) in-life portion

  21. Slide 21: KIND-012 Pilot Study Results (IV)

    21 KIND-012 – Pilot Study Results (IV) Randomized, blinded, placebo-controlled, crossover study (N=31) Primary endpoint was improvement or resolution of fever Response – First dose Response – Crossover Dose Placebo KIND-012 n 16 15 Response Rate (%) 2 (12.5) 10 (66.7) p-value 0.0032 Placebo KIND-012

  22. Slide 22: KIND-012 Pilot Study Results (IV): Mean Temperature

    22 KIND-012 – Pilot Study Results (IV) Mean Temp. over Time - First Dose and Crossover Dose (Treated Pts.) First Dose 6 Hours Post First Dose Crossover Dose 6 Hours Post Crossover Dose Te m pe ra tu re (F ) 97 98 99 100 101 102 103 104 105 106 Scheduled Visit (Hours Relative to First Dose) -5 0 5 10

  23. Slide 23: KB0120 Pivotal Field Study Results (IV)

    23 KB0120 Pivotal Field Study Results (IV) Randomized, double-blind, placebo-controlled (N=138) Primary endpoint was improvement or resolution of fever Placebo KIND-012 n 34 104 Success Rate (%) 7 (approx. 20%) 78 (approx. 75%) p-value < 0.0001

  24. Slide 24: KIND-010: Weight Loss in Cats

    24 KIND-010 Transdermal drug for the management of weight loss in cats High unmet medical need Current drugs often not effective 90% of veterinarians treat cats with inappetence (average of 7 cats per week) PK studies completed - positive efficacy signal, as evidenced by increase in weight Pilot stu

  25. Slide 25: Biologics

    25 Biologics Highly experienced biologics team Extensive experience developing Lucentis, Xolair, Tysabri, Avastin, Rituxan, Herceptin, Enbrel, and multiple other biologics Internal caninization/felinization/equinization expertise Promising biologics candidates Feline erythropoietin Checkpoint inhibi

  26. Slide 26: New Scaffold Technology: KIND-Body

    26 New Scaffold Technology: KIND-Body A proprietary, non-antibody scaffold technology being developed by KindredBio Binding affinity similar to antibodies Bispecific binding possible Could allow KindredBio to pursue biologics targets before other parties’ antibody patents expire

  27. Slide 27: KIND-510 Feline Erythropoietin

    27 KIND-510 Feline Erythropoietin Proprietary recombinant feline erythropoietin Strong internal expertise in erythropoietin biology and engineering Initial laboratory study completed - positive efficacy signal, as evidenced by increased reticulocyte formation Pilot field study to begin shortly High

  28. Slide 28: Key Focus Area: Atopic Dermatitis

    28 Key Focus Area: Atopic Dermatitis Atopic dermatitis is a large market Apoquel® projected peak sales >$200M Multiple antibody candidates Anti-IgE antibody Anti-IL17a antibody Anti-IL4R antibody Anti-IL31 antibody Anti-CD20 antibody Expect proof-of-concept data with some of the initial antibody var

  29. Slide 29: Key Focus Area: Cancer

    29 Key Focus Area: Cancer Multiple antibody candidates Anti-CTLA4 antibody Anti-PD1 antibody Anti-PDL1 antibody Anti-CD20 antibody

  30. Slide 30: Strategic Shift Toward Biologics

    30 Strategic Shift Toward Biologics Will increase biologics headcount and increase laboratory space Counterbalanced by headcount reduction in other areas, including small molecule CMC (expect approximately $700K restructuring charge in Q1) Expect annual cash burn to remain at approximately $25M per

  31. Slide 31: Manufacturing Plant

    31 Manufacturing Plant In-house biologics manufacturing plant nearly complete Single-use, state of the art system Will allow full GMP commercial production of feline epo Will allow full GMP clinical and early commercial production of antibodies

  32. Slide 32: Commercialization

    32 Commercialization

  33. Slide 33: Commercialization

    33 Commercialization Equine Commercialization: Launch and commercialize our U.S. products with ~10 person direct sales force Dog/Cat Commercialization Options: Self-Commercialization Out-license Partner for 3 – 5 years, and then transition to KindredBio salesforce

  34. Slide 34: Low Generic Penetration

    34 Few pet generic companies No automatic substitution Requires sales & marketing effort Rimadyl reached peak sales several years after loss of exclusivity Low Generic Penetration Note: Companion Animal dispensing rate within the veterinary clinic. Source: IMS Health, Putney, BofA Merril Lynch Globa

  35. Slide 35: Exclusivity and IP Position

    35 Exclusivity and IP Position Full intellectual property protection anticipated for antibody portfolio Use and formulation patents for small molecules 20 years of patent protection from date of filing Regulatory Exclusivity 5 years in U.S. 10 years in E.U. Lifecycle Management New formulations, com

  36. Slide 36: Business Development

    36 Business Development In active discussions about acquisitions of businesses and/or assets, particularly of equine assets Ideal candidate: Revenue generating/accretive Commercial infrastructure Complementary assets

  37. Slide 37: Finances

    37 Finances

  38. Slide 38: Select Summary Financials

    38 Select Summary Financials $ millions For the quarter ended September 30, 2015 Operating expenses: Research and development $5.0 General and administrative $2.1 Total cash operating expenses (excluding stock-based compensation) $6.1 Total operating expenses (including stock-based compensation) $7.

  39. Slide 39: Summary

    39 Summary Validated Drugs and Targets $3M-$5M to Market Multiple Approvals Starting within 2 years World Class Team

  40. Slide 40: Thank You

    40 Thank You

Kindred Biosciences — Investor Presentation (January 2016) on 6ix